Evidence map›Paper›PMID 37014128›Full record

ArticleMolecular oncology2023

Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.

Esther P Jane, Matthew C Reslink, Taylor A Gatesman, Matthew E Halbert, Tracy A Miller, Brian J Golbourn, Stephanie M Casillo, Steven J Mullett, Stacy G Wendell, Udochukwu Obodo and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Esther P JaneDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Matthew C ReslinkDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Taylor A GatesmanDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Matthew E HalbertDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Tracy A MillerDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Brian J GolbournDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Stephanie M CasilloDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Steven J MullettDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, PA, USA.
Stacy G WendellDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, PA, USA.
Udochukwu ObodoDepartment of Diabetes & Cancer Metabolism, City of Hope Medical Center, Duarte, CA, USA.
Dinesh MohanakrishnanDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Riya DangeDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Antony MichealrajDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Charles BrennerDepartment of Diabetes & Cancer Metabolism, City of Hope Medical Center, Duarte, CA, USA.
Sameer AgnihotriDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
Daniel R PremkumarDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.ORCID 0000-0001-6885-0632
Ian F PollackDepartment of Neurosurgery, University of Pittsburgh School of Medicine, PA, USA.
University of Pittsburgh · USCity Of Hope National Medical Center · US

Funding

Targeting extracellular signaling-regulated kinase 5 (ERK5) in brain tumors and their microenvironmentR01NS115831 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AGNIHOTRI, SAMEER · 2020 to 2024
$1.8M
An Exploris 240 for MetabolomicsS10OD032141 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GELHAUS, STACY LYNN · 2022 to 2022
$600k
Bringing Untargeted Metabolomics to PittS10OD023402 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GELHAUS, STACY LYNN · 2018 to 2018
$594k
NIH HHS S10 OD023402NIH HHS S10 OD032141NINDS NIH HHS R01 NS115831
6 · The paper itself

Abstract

In previous studies, we demonstrated that panobinostat, a histone deacetylase inhibitor, and bortezomib, a proteasomal inhibitor, displayed synergistic therapeutic activity against pediatric and adult high-grade gliomas. Despite the remarkable initial response to this combination, resistance emerged. Here, in this study, we aimed to investigate the molecular mechanisms underlying the anticancer effects of panobinostat and marizomib, a brain-penetrant proteasomal inhibitor, and the potential for exploitable vulnerabilities associated with acquired resistance. RNA sequencing followed by gene set enrichment analysis (GSEA) was employed to compare the molecular signatures enriched in resistant compared with drug-naïve cells. The levels of adenosine 5'-triphosphate (ATP), nicotinamide adenine dinucleotide (NAD)

Indexed as

GliomaNADAdultCell Line, TumorChildHumansLactonesMitochondriaPanobinostatProteasome InhibitorsPyrrolesLactonesmarizomibNADPanobinostatProteasome InhibitorsPyrrolesgliomamarizomibmitochondriaOXPHOSpanobinostatresistance

Identifiers

PMID37014128
PMCPMC10483615
OpenAlexW4362523354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.